NGM Biopharmaceuticals, Inc. (NGM) Bundle
A Brief History of NGM Biopharmaceuticals, Inc. (NGM)
Foundation and Early Development
Foundation and Early Development
NGM Biopharmaceuticals, Inc. was founded in 2008. The company was established with a vision to develop innovative therapeutics primarily targeting serious diseases, leveraging their proprietary technology platforms.
Initial Funding Rounds
In its early years, NGM secured substantial funding to facilitate research and development. The company raised approximately $1.8 billion in total financing from various rounds, including Series A, B, and C, involving prominent investors and venture capital firms.
Key Partnerships
NGM entered into a significant collaboration with Merck & Co. in 2016 to develop and commercialize new therapeutics in the field of metabolic diseases. This partnership included an upfront payment of $50 million along with potential milestone payments that could exceed $1 billion.
IPO and Public Offering
NGM Biopharmaceuticals went public on December 10, 2019. The initial public offering (IPO) was priced at $17 per share, raising approximately $150 million before expenses. The shares began trading on the NASDAQ under the ticker symbol NGM.
Clinical Development Pipeline
The company's pipeline includes several promising candidates targeting areas such as oncology and metabolic diseases. NGM621, an investigational treatment for geographic atrophy, entered clinical trials in 2020.
| Drug Candidate | Indication | Phase | Clinical Trial Start Year | Current Status |
|---|---|---|---|---|
| NGM621 | Geographic Atrophy | Phase II | 2020 | Ongoing |
| NGM383 | Non-alcoholic Steatohepatitis (NASH) | Phase I | 2021 | Ongoing |
| NGM120 | Multiple Cancers | Phase I | 2020 | Ongoing |
| NGM149 | Metabolic Disorders | Phase I | 2020 | Ongoing |
Financial Performance
For the fiscal year 2022, NGM reported total revenue of $12.5 million, primarily from collaborations and licensing agreements. The net loss for the same year was reported at $78.4 million, reflecting the company's heavy investment in R&D.
Recent Developments
In 2023, NGM announced its strategic shift focusing on precision medicine and expanding its pipeline to include autoimmune diseases. The company expects to initiate several new clinical trials in the upcoming years.
Market Position and Valuation
As of mid-2023, NGM Biopharmaceuticals’ market capitalization stands at approximately $300 million. The company's progress in clinical trials and potential new product approvals continue to influence its valuation and investor interest.
A Who Owns NGM Biopharmaceuticals, Inc. (NGM)
Ownership Structure
Ownership Structure
As of the latest filings, NGM Biopharmaceuticals, Inc. has a diverse ownership structure, which includes institutional investors, insiders, and retail investors. The following table presents the breakdown of ownership percentages.
| Ownership Type | Percentage |
|---|---|
| Institutional Investors | 75.2% |
| Insider Ownership | 10.5% |
| Retail Investors | 14.3% |
Major Institutional Shareholders
The following table lists the major institutional shareholders of NGM Biopharmaceuticals, Inc. along with their respective ownership stakes.
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| The Vanguard Group, Inc. | 3,500,000 | 12.5% |
| BlackRock, Inc. | 3,200,000 | 11.4% |
| Fidelity Investments | 2,800,000 | 10.0% |
| State Street Global Advisors | 2,500,000 | 8.9% |
| Invesco Ltd. | 1,800,000 | 6.4% |
Insider Ownership Details
The following table outlines the ownership stakes held by key insiders of NGM Biopharmaceuticals, Inc.
| Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| David J. Stump | CEO | 1,000,000 | 3.6% |
| Benny J. Shmulevitz | Chairman | 750,000 | 2.7% |
| Kurt R. Gunter | COO | 500,000 | 1.8% |
Recent Stock Performance
As of October 2023, NGM Biopharmaceuticals has seen fluctuating stock performance. The following table displays the recent stock price and market capitalization.
| Stock Price (USD) | Market Capitalization (USD) | 52-Week High (USD) | 52-Week Low (USD) |
|---|---|---|---|
| 15.25 | 1.0 Billion | 20.00 | 10.50 |
Future Outlook and Projections
Analysts project that NGM Biopharmaceuticals will continue to grow its market presence. The following table presents the projected revenue growth over the next five years.
| Year | Projected Revenue (USD Millions) | Growth Rate (%) |
|---|---|---|
| 2024 | 100 | 20% |
| 2025 | 120 | 20% |
| 2026 | 144 | 20% |
| 2027 | 172.8 | 20% |
| 2028 | 207.36 | 20% |
NGM Biopharmaceuticals, Inc. (NGM) Mission Statement
Company Overview
NGM Biopharmaceuticals, Inc. focuses on discovering and developing transformative therapies for patients with severe diseases. Their mission statement emphasizes the commitment to leveraging proprietary discovery platforms to bring innovative drugs to market.
Mission Statement Details
- Objective: To improve the lives of patients by addressing unmet medical needs.
- Core Values: Innovation, Integrity, and Excellence.
- Focus Areas: Metabolic diseases, cancer, and neurodegeneration.
Current Pipeline Overview
The pipeline includes several drug candidates in various stages of clinical trials. As of the latest update:
| Drug Candidate | Indication | Phase | Expected Milestone |
|---|---|---|---|
| NGM621 | Diabetic Retinopathy | Phase 2 | Data Readout in Q4 2023 |
| NGM282 | Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Data Readout in Q1 2024 |
| NGM393 | Oncology | Phase 1 | Initial Data in H2 2024 |
Financial Overview
As of the latest fiscal report, NGM Biopharmaceuticals has demonstrated significant financial metrics:
| Financial Metric | Amount (in USD) | Year |
|---|---|---|
| Total Revenue | $0.00 | 2022 |
| Net Loss | ($93.8 million) | 2022 |
| Cash and Cash Equivalents | $211.7 million | As of Q2 2023 |
Strategic Collaborations
NGM has established key collaborations to enhance its R&D capabilities and market reach:
- Collaboration with Merck & Co., Inc. for the development of NGM313.
- Partnership with other biotech firms to expand research in metabolic diseases.
Corporate Impact
The company is committed to corporate responsibility and sustainability, focusing on:
- Innovative drug development that prioritizes patient safety.
- Community engagement and support through various health initiatives.
Conclusion on Mission Alignment
NGM Biopharmaceuticals aligns its operational strategies with its mission statement, focusing on innovative solutions for critical health challenges.
How NGM Biopharmaceuticals, Inc. (NGM) Works
Company Overview
NGM Biopharmaceuticals, Inc. (NGM) was founded in 2008 and operates in the field of biopharmaceuticals, specifically focusing on the discovery, development, and commercialization of treatments for various diseases. As of 2023, NGM has a market capitalization of approximately $350 million.
Business Model
The company employs a discovery-driven approach, utilizing its proprietary technology platforms to identify and develop innovative therapeutic candidates. NGM’s business model is built around two main areas:
- Therapeutics for metabolic and endocrine disorders.
- Oncology therapeutics.
Research and Development Pipeline
As of the latest report, NGM has several candidates in different stages of clinical trials:
| Product Candidate | Indication | Phase of Development | Expected Milestones |
|---|---|---|---|
| NGM313 | Oncology | Phase 2 | Data readout expected Q4 2023 |
| NGM621 | Diabetic Retinopathy | Phase 2 | Data readout expected Q1 2024 |
| NGM120 | Metabolic Disorders | Phase 1 | Initial data by mid-2024 |
Financial Performance
In the fiscal year 2022, NGM reported a revenue of $14.5 million, a slight increase from $12.8 million in 2021. The company has primarily relied on partnerships for funding, securing over $300 million from collaborations.
As of Q3 2023, NGM's total expenditures were reported at $28 million, with the majority allocated towards research and development, accounting for approximately 72% of total expenses.
Partnerships and Collaborations
NGM has entered into strategic collaborations to enhance its research capabilities and funding. Key partnerships include:
- Merck & Co., Inc. - Collaboration focusing on the development of new therapies.
- AbbVie - Partnership aimed at discovering new cancer treatments.
Market Presence
NGM operates primarily in the United States but is also exploring opportunities in Europe and Asia. The company’s stock trades on the Nasdaq under the symbol NGM. The trading price as of October 2023 is $4.50 per share.
Clinical Trial Results
NGM has reported interim results from recent trials:
| Trial Name | Drug Candidate | Indication | Primary Endpoint Results |
|---|---|---|---|
| Trial 1 | NGM313 | Oncology | Positive efficacy observed in 45% of patients |
| Trial 2 | NGM621 | Diabetic Retinopathy | Significant improvement in vision scores |
| Trial 3 | NGM120 | Weight Loss | Met primary endpoint in 65% of participants |
Regulatory Status
NGM has submitted multiple Investigational New Drug (IND) applications to the FDA and has received Fast Track and Orphan Drug Designation for certain candidates, expediting the development process.
Future Outlook
The pipeline expansion is a priority for NGM, aiming to enter new indications and strengthen its market position. The company is also assessing potential mergers and acquisitions to enhance its portfolio.
Recent Developments
In September 2023, NGM announced a partnership agreement with a biotechnology firm to co-develop a novel therapeutic platform aimed at rare genetic disorders.
How NGM Biopharmaceuticals, Inc. (NGM) Makes Money
Revenue Streams
Revenue Streams
NGM Biopharmaceuticals, Inc. generates revenue primarily through the development and commercialization of innovative therapeutic solutions. The company focuses on a variety of therapeutic areas, including metabolic diseases, oncology, and infectious diseases.
Partnerships and Collaborations
NGM engages in strategic collaborations with major pharmaceutical companies to enhance its research and development capabilities. These partnerships often involve milestone payments and royalties on sales from products developed through these collaborations.
| Partner Company | Collaboration Focus | Milestone Payments (in million $) | Royalty Rate (%) |
|---|---|---|---|
| Merck & Co. | Oncology | 50 | 10-20 |
| AbbVie | Metabolic Diseases | 75 | 15-25 |
| Janseen Pharmaceuticals | Neurology | 40 | 12-18 |
Product Development Pipeline
NGM has a robust product pipeline which includes several candidates in various stages of clinical trials. Successful development leads to potential revenue through product launches and sales.
| Product Candidate | Indication | Phase of Development | Projected Launch Year |
|---|---|---|---|
| NGM621 | Diabetic Retinopathy | Phase 3 | 2024 |
| NGM383 | Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 2025 |
| NGM120 | Oncology | Phase 2 | 2026 |
Licensing Agreements
Licensing agreements contribute significantly to NGM's revenue. The company licenses its proprietary technologies or compounds to other firms in exchange for upfront fees, milestone payments, and royalties.
| Technology Licensed | Licensee | Upfront Fee (in million $) | Potential Milestone Payments (in million $) |
|---|---|---|---|
| Gene Therapy Platform | Company X | 30 | 100 |
| Antibody Discovery Technology | Company Y | 25 | 70 |
| Small Molecule Library | Company Z | 20 | 50 |
Financial Performance
In the latest financial reports, NGM Biopharmaceuticals, Inc. reported total revenue of $120 million for the fiscal year ended 2022. The revenue is derived from partnerships, product sales, and licensing agreements.
| Financial Metrics | 2022 | 2021 | 2020 |
|---|---|---|---|
| Total Revenue (in million $) | 120 | 85 | 60 |
| Net Income (in million $) | 10 | (5) | (12) |
| Research and Development Expenses (in million $) | 70 | 60 | 50 |
| Operating Expenses (in million $) | 30 | 25 | 20 |
NGM Biopharmaceuticals, Inc. (NGM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support